eadable Nucleotide Sequence Listing as a part of specification included in the international pul

SEQUENCE LISTING

<110> PROTEIN DESIGN LAB, LTD.

<120> NOVEL ANTIBIOTIC PREPARATION METHOD AND PLATFORM SYSTEM BASED ON SAME

<130> P121219-CN-CN-JJQ

<160> 33

<170> PatentIn version 3.5

<210> 1
<211> 625
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutant of colicin mutamer Ia

<400> 1

```
Ser Asp Pro Val Arg Ile Thr Asn Pro Ala Ala Glu Ser Leu Gly Tyr
1               5                  10                  15

Asp Ser Asp Gly Gly Glu Ile Met Gly Val Asp Ile Tyr Leu Asn Pro
            20                  25                  30

Pro Arg Val Asp Val Phe Asp Gly Thr Pro Pro Ala Trp Ser Ser Phe
        35                  40                  45

Gly Asn Lys Thr Ile Trp Gly Gly Asn Glu Trp Val Asp Asp Ser Pro
    50                  55                  60

Thr Arg Ser Asp Ile Glu Lys Arg Asp Lys Glu Ile Thr Ala Tyr Lys
65                  70                  75                  80

Asn Thr Leu Ser Ala Gln Gln Lys Glu Asn Glu Asn Lys Arg Thr Glu
                85                  90                  95

Ala Gly Lys Arg Leu Ser Ala Ala Ile Ala Ala Arg Glu Lys Asp Glu
            100                 105                 110

Asn Thr Leu Lys Thr Leu Arg Ala Gly Asn Ala Asp Ala Ala Asp Ile
        115                 120                 125

Thr Arg Gln Glu Phe Arg Leu Leu Gln Ala Glu Leu Arg Glu Tyr Gly
    130                 135                 140

Phe Arg Thr Glu Ile Ala Gly Tyr Asp Ala Leu Arg Leu His Thr Glu
145                 150                 155                 160

Ser Arg Met Leu Phe Ala Asp Ala Asp Ser Leu Arg Ile Ser Pro Arg
                165                 170                 175

Glu Ala Arg Ser Leu Ile Glu Gln Ala Glu Lys Arg Gln Lys Asp Ala
            180                 185                 190
```

Gln Asn Ala Asp Lys Lys Ala Ala Asp Met Leu Ala Glu Tyr Glu Arg
195 200 205

Arg Lys Gly Ile Leu Asp Thr Arg Leu Ser Glu Leu Glu Lys Asn Gly
210 215 220

Gly Ala Ala Leu Ala Val Leu Asp Ala Gln Gln Ala Arg Leu Leu Gly
225 230 235 240

Gln Gln Thr Arg Asn Asp Arg Ala Ile Ser Glu Ala Arg Asn Lys Leu
245 250 255

Ser Ser Val Thr Glu Ser Leu Asn Thr Ala Arg Asn Ala Leu Thr Arg
260 265 270

Ala Glu Gln Gln Leu Thr Gln Gln Lys Asn Thr Pro Asp Gly Lys Thr
275 280 285

Ile Val Ser Pro Glu Lys Phe Pro Gly Arg Ser Ser Thr Asn His Ser
290 295 300

Ile Val Val Ser Gly Asp Pro Arg Phe Ala Gly Thr Ile Lys Ile Thr
305 310 315 320

Thr Ser Ala Val Ile Asp Asn Arg Ala Asn Leu Asn Tyr Leu Leu Ser
325 330 335

His Ser Gly Leu Asp Tyr Lys Arg Asn Ile Leu Asn Asp Arg Asn Pro
340 345 350

Val Val Thr Glu Asp Val Glu Gly Asp Lys Lys Ile Tyr Asn Ala Glu
355 360 365

Val Ala Glu Trp Asp Lys Leu Arg Gln Arg Leu Leu Asp Ala Arg Asn
370 375 380

Lys Ile Thr Ser Ala Glu Ser Ala Val Asn Ser Ala Arg Asn Asn Leu
385 390 395 400

Ser Ala Arg Thr Asn Glu Gln Lys His Ala Asn Asp Ala Leu Asn Ala
405 410 415

Leu Leu Lys Glu Lys Glu Asn Ile Arg Asn Gln Leu Ser Gly Ile Asn
420 425 430

Gln Lys Ile Ala Glu Glu Lys Arg Lys Gln Asp Glu Leu Lys Ala Thr
435 440 445

Lys Asp Ala Ile Asn Phe Thr Thr Glu Phe Leu Lys Ser Val Ser Glu
450 455 460

Lys Tyr Gly Ala Lys Ala Glu Gln Leu Ala Arg Glu Met Ala Gly Gln
465 470 475 480

Ala Lys Gly Lys Lys Ile Arg Asn Val Glu Glu Ala Leu Lys Thr Tyr
485 490 495

Glu Lys Tyr Arg Ala Asp Ile Asn Lys Lys Ile Asn Ala Lys Asp Arg
500 505 510

Ala Ala Ile Ala Ala Ala Leu Glu Ser Val Lys Leu Ser Asp Ile Ser
515 520 525

Ser Asn Leu Asn Arg Phe Ser Arg Gly Leu Gly Tyr Ala Gly Lys Phe
530 535 540

Thr Ser Leu Ala Asp Trp Ile Thr Glu Phe Gly Lys Ala Val Arg Thr
545 550 555 560

Glu Asn Trp Arg Pro Leu Phe Val Lys Thr Glu Thr Ile Ile Ala Gly
565 570 575

Asn Ala Ala Thr Ala Leu Val Ala Leu Val Phe Ser Ile Leu Thr Gly
580 585 590

Ser Ala Leu Gly Ile Ile Gly Tyr Gly Leu Leu Met Ala Val Thr Gly
595 600 605

Ala Leu Ile Asp Glu Ser Leu Val Glu Lys Ala Asn Lys Phe Trp Gly
610 615 620

Ile
625

<210> 2
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> VHCDR1-VHFR2-VLCDR3

<400> 2

Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu
1 5 10 15

Trp Val Ala Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr
20 25

<210> 3
<211> 28
<212> PRT
<213> Artificial Sequence

eadable Nucleotide Sequence Listing as a part of specification included in the international pub

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 3

Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu
1 5 10 15

Trp Val Ala Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr
20 25

<210> 4
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 4

Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu
1 5 10 15

Trp Val Ala Gln Gln Trp Ser Ser Asn Pro Tyr Thr
20 25

<210> 5
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 5

Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu
1 5 10 15

Trp Val Ala Leu Gln Gly Thr His Gln Pro Tyr Thr
20 25

<210> 6
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 6

Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu
1 5 10 15

Trp Val Ala Gln Gln Leu His Phe Tyr Pro His Thr
20 25

eadable Nucleotide Sequence Listing as a part of specification included in the international pul

<210> 7
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 7

Arg Gln Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu
1 5 10 15

Trp Val Ala Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr
20 25

<210> 8
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> VHCDR1-VHFR2-VLCDR3

<400> 8

Ser Tyr Trp Leu His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Trp
1 5 10 15

Ile Gly Ser Gln Ser Thr His Val Pro Arg Thr
20 25

<210> 9
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 9

Ser Tyr Gly Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Trp
1 5 10 15

Ile Gly Ser Gln Ser Thr His Val Pro Arg Thr
20 25

<210> 10
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 10

Ser Tyr Trp Ile Glu Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Trp
1 5 10 15

eadable Nucleotide Sequence Listing as a part of specification included in the international pul

Ile Gly Ser Gln Ser Thr His Val Pro Arg Thr
20 25

<210> 11
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 11

Asn Tyr Trp Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Trp
1 5 10 15

Ile Gly Ser Gln Ser Thr His Val Pro Arg Thr
20 25

<210> 12
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 12

Ser Tyr Trp Leu His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Trp
1 5 10 15

Ile Gly Met Gln Asn Ile Gly Leu Pro Trp Thr
20 25

<210> 13
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 13

Ser Tyr Trp Leu His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Trp
1 5 10 15

Ile Gly Gln Gln Phe Thr Ser Ser Pro Tyr Thr
20 25

<210> 14
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> VHCDR1-VHFR2-VLCDR3

<400> 14

eadable Nucleotide Sequence Listing as a part of specification included in the international pul

Ser Thr Ala Leu His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Pro Arg Tyr Asp Glu Phe Pro Tyr Thr
20 25

<210> 15
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 15

Ser Phe Gly Met His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Pro Arg Tyr Asp Glu Phe Pro Tyr Thr
20 25

<210> 16
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 16

Asn Tyr Trp Met His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Pro Arg Tyr Asp Glu Phe Pro Tyr Thr
20 25

<210> 17
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 17

Ser Thr Ala Leu His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Phe Gln Gly Ser His Val Pro Phe Thr
20 25

<210> 18
<211> 26
<212> PRT
<213> Artificial Sequence

<220>

eadable Nucleotide Sequence Listing as a part of specification included in the international pul

<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 18

Ser Thr Ala Leu His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Tyr Cys His Gln Trp Ser Met Tyr Thr
20 25

<210> 19
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 19

Ser Thr Ala Leu His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Gln Gln Trp Ser Ser Asn Pro Tyr Thr
20 25

<210> 20
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 20

Ser Thr Ala Leu His Trp Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
1 5 10 15

Val Gln Gln Phe Thr Ser Ser Pro Tyr Thr
20 25

<210> 21
<211> 14
<212> PRT
<213> Candida Albicans

<400> 21

Gly Phe Arg Leu Tyr Asn Phe Gly Tyr Phe Glu Pro Gly Lys
1 5 10

<210> 22
<211> 8
<212> PRT
<213> Staphyloccocus aureus

<400> 22

Tyr Ser Thr Cys Asp Phe Ile Met
1 5

eadable Nucleotide Sequence Listing as a part of specification included in the international pub

<210> 23
<211> 9
<212> PRT
<213> Staphyloccocus aureus

<400> 23

Gly Val Asn Ala Cys Ser Ser Leu Phe
1 5

<210> 24
<211> 8
<212> PRT
<213> Staphyloccocus aureus

<400> 24

Tyr Ile Asn Cys Asp Phe Leu Leu
1 5

<210> 25
<211> 8
<212> PRT
<213> Staphyloccocus aureus

<400> 25

Tyr Ser Thr Cys Tyr Phe Ile Met
1 5

<210> 26
<211> 8
<212> PRT
<213> Staphylococcus epidermidis

<400> 26

Asp Ser Val Cys Ala Ser Tyr Phe
1 5

<210> 27
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> VHCDR1-VHFR2-VLCDR3

<400> 27

Ser Tyr Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Gln Tyr Trp Ser Thr Pro Pro Trp Thr
20 25

<210> 28
<211> 29
<212> PRT
<213> Artificial Sequence

eadable Nucleotide Sequence Listing as a part of specification included in the international pub

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 28

Ser Tyr Gly Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Gln Tyr Trp Ser Thr Pro Pro Trp Thr
20 25

<210> 29
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 29

Asp His Tyr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Gln Tyr Trp Ser Thr Pro Pro Trp Thr
20 25

<210> 30
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 30

Ser Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Gln Tyr Trp Ser Thr Pro Pro Trp Thr
20 25

<210> 31
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 31

Ser Tyr Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Gln Gln Phe Thr Ser Ser Pro Trp Thr
20 25

eadable Nucleotide Sequence Listing as a part of specification included in the international pul

<210> 32
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 32

Ser Tyr Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Gln Gln Ser Arg Glu Tyr Pro Tyr Thr
20 25

<210> 33
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Point-mutant of VHCDR1-VHFR2-VLCDR3

<400> 33

Ser Tyr Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
1 5 10 15

Trp Ile Gly Gln Leu Gln Gly Thr His Gln Pro Tyr Thr
20 25